Katsuaki Maehara

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Katsuaki Maehara
Dec 7, 2024, 02:08 | Insight
Katsuaki Maehara: Is the colon an organ that differs from the right side to the left side?
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: “Molecular Cancer. Is…
Dec 2, 2024, 09:46 | Positive
Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As November came to a close, it's an ideal time to reflect on Lung Cancer…
Nov 25, 2024, 08:08 | Blog
Katsuaki Maehara: EGFR structure
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: "EGFR structure. Tyrosine kinase…
Nov 16, 2024, 20:00 | Blog
Katsuaki Maehara: Non-G12C KRAS mutations
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: "Non-G12C KRAS mutations:…
Nov 9, 2024, 18:17 | Blog
Katsuaki Maehara: Using targeted NGS analysis for EGFR classical mutations in NSCLC
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: “EGFR classical mutated NSCLC Frequency…
Oct 29, 2024, 17:46 | Insight
Katsuaki Maehara: EGFRm Unresectable Stage III lung cancer in LAURA and POLESTAR trials
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: “EGFRm Unresectable Stage…
Oct 25, 2024, 16:19 | Insight
EGFR-mutated oligo-organ metastatic NSCLC, summarised by Katsuaki Maehara
Katsuaki Maehara ,Director of Medical Education Colleagues, shared a post on X: " EGFR-mutated oligo-organ…
Oct 14, 2024, 13:56 | Insight
Katsuaki Maehara: Comprehensive Genome Profiling using NGS
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: “Comprehensive Genome Profiling…
Oct 11, 2024, 15:17 | Blog
Katsuaki Maehara: Summary of Major Clinical Trials of ICI's in Early Stage NSCLC
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: ''Summary of Major…
Oct 5, 2024, 16:04 | Societies
Highlights From ILCS24
The 6th International Lung Cancer Summit was held in Lausanne, Switzerland on October 4, 2024,…
Aug 19, 2024, 11:57 | Insight
Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma
Katsuaki Maehara shared a post on X: "Melanoma Journal of Clinical Oncology. NCCN Guidelines recommended both…
Aug 14, 2024, 07:04 | Insight
ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X, about recent paper…
Aug 13, 2024, 11:55 | Blog
Katsuaki Maehara: Uncommon EGFR Mutations and the variability in therapeutic efficacy
Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: "Uncommon EGFR mutations…
Aug 10, 2024, 13:45 | Insight
Katsuaki Maehara: EGFR mutated NSCLC
Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: “EGFR mutated NSCLC.…
Aug 8, 2024, 03:46 | Blog
Katsuaki Maehara: Importance of Sin3a in the stable expression of Foxp3 in Tregs
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X, about recent paper…
Aug 5, 2024, 07:03 | Insight
Katsuaki Maehara: Removal of ICIs resistance by CAF-derived TSG-6 inhibition
Katsuaki Maehara, Cancer Biologist, shared a post on X: "Removal of ICIs resistance by CAF-derived…
Jul 28, 2024, 10:33 | Insight
Katsuaki Maehara: New histopathologic indices to predict postoperative recurrence of lung cancer
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X about a recent…
Jul 14, 2024, 07:21 | Drugs
Drug list Ver 3 for mNSCLC: 1st line EGFR common mutations
Katsuaki Maehara, Director of Medical Education Colleagues, shared on X: "Lung - NSCLC Drug list…
Jun 29, 2024, 07:45 | Insight
Katsuaki Maehara: The changes in TME and TKI treatment resistance by EGFR and ALK TKI
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X:       …
May 22, 2024, 00:34 | Insight
Katsuaki Maehara: NSCLC updated
Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: "NCCN Guidelines updated.…
Apr 5, 2024, 17:48 | Blog
Katsuaki Maehara: Updated Oncology Drug List, Ver.2
Katsuaki Maehara, Director of Medical Education Colleagues, posted the following on X: “Updated Oncology Drug…
Feb 2, 2024, 12:30 | Blog
Katsuaki Maehara: I have compiled a list of NSCLC drugs for 2024
Katsuaki Maehara, Director of Medical Education Colleagues, posted the following on X: "NSCLC Drug List…
Dec 31, 2023, 20:07 | Blog
Katsuaki Maehara: Patritumab Deruxtecan (HER3-DXd) clinical trial transition
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared a post by EGFR Resisters on X/Twitter,…
Dec 23, 2023, 03:25 | Drugs
Katsuaki Maehara: Therapeutic development of 4th generation TKIs is active for acquired resistance to osimelnitinib for C797
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on X/Twitter: "Therapeutic development…
Dec 5, 2023, 18:49 | Blog
Katsuaki Maehara: Stage Ⅳ EGFRm NSCLC - Sequential Treatment Options
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on Twitter: "Stage Ⅳ…
Nov 11, 2023, 17:08 | Blog
Katsuaki Maehara: Great article about ADCs by Paolo Tarantino
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on X/Twitter: "Great article…
All: 26 Posts: 1 - 100
Special Coverage